XML 26 R18.htm IDEA: XBRL DOCUMENT
v3.24.3

Stockholders' Deficit | 9 Months Ended
--- | ---
Sep. 30, 2024
Equity [Abstract] |
STOCKHOLDERS' DEFICIT | 10. STOCKHOLDERS’ DEFICIT Authorized capital shares of the Company include 400,000,000 shares of capital stock consisting of 300,000,000 shares of common stock and 100,000,000 shares of preferred stock. Each of the aforementioned classes of capital stock has a par value of $0.01 per share. Shares of preferred stock, none of which were outstanding as of September 30, 2024, may be issued in one or more series having such rights, preferences and other provisions as determined by the Board of Directors without approval by the holders of common stock. The Company is a holding company, which operates through its subsidiaries. The ABL Facility and the indentures governing each series of the Company’s outstanding notes contain various covenants under which the assets of the subsidiaries of the Company are subject to certain restrictions relating to, among other matters, dividends and distributions, as referenced in the paragraph below. The ABL Facility and the indentures governing each series of the Company’s outstanding notes restrict the Company’s subsidiaries from, among other matters, paying dividends and making distributions to the Company, which thereby limits the Company’s ability to pay dividends and/or repurchase stock. As of September 30, 2024, under the most restrictive test in these agreements (and subject to certain exceptions), the Company has approximately $300 million of capacity to pay permitted dividends and/or repurchase shares of stock or make other restricted payments. The schedule below presents the reconciliation of the carrying amount of total equity, equity attributable to the Company’s stockholders, and equity attributable to noncontrolling interests as of September 30, 2024, and during each of the three-month periods following December 31, 2023 (in millions).
|  |  |  |  |  | Community Health Systems, Inc. Stockholders |  |  |  |  |  |  |
|  | Redeemable Noncontrolling Interest |  |  |  | Common Stock |  |  | Additional Paid-In Capital |  |  | Accumulated Other Comprehensive (Loss) Income |  |  | Accumulated Deficit |  |  | Noncontrolling Interest |  |  | Total Stockholders’ Deficit |
Balance, December 31, 2023 |  | $ | 323 |  |  |  | $ | 1 |  |  | $ | 2,185 |  |  | $ | (14 | ) |  | $ | (3,564 | ) |  | $ | 245 |  |  | $ | (1,147 | )
Comprehensive income (loss) |  |  | 16 |  |  |  |  | — |  |  |  | — |  |  |  | (2 | ) |  |  | (41 | ) |  |  | 19 |  |  |  | (24 | )
Distributions to noncontrolling interests |  |  | (17 | ) |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (33 | ) |  |  | (33 | )
Adjustment to redemption value of redeemable noncontrolling interests |  |  | (3 | ) |  |  |  | — |  |  |  | 3 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3 |
Cancellation of restricted stock for tax withholdings on vested shares |  |  | — |  |  |  |  | — |  |  |  | (2 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (2 | )
Other reclassifications of noncontrolling interests |  |  | 10 |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (10 | ) |  |  | (10 | )
Share-based compensation |  |  | — |  |  |  |  | — |  |  |  | 6 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 6 |
Balance, March 31, 2024 |  |  | 329 |  |  |  |  | 1 |  |  |  | 2,192 |  |  |  | (16 | ) |  |  | (3,605 | ) |  |  | 221 |  |  |  | (1,207 | )
Comprehensive income (loss) |  |  | 15 |  |  |  |  | — |  |  |  | — |  |  |  | 3 |  |  |  | (14 | ) |  |  | 25 |  |  |  | 14 |
Distributions to noncontrolling interests |  |  | (14 | ) |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (20 | ) |  |  | (20 | )
Purchases of subsidiary shares from noncontrolling interests |  |  | 1 |  |  |  |  | — |  |  |  | (2 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (2 | )
Adjustment to redemption value of redeemable noncontrolling interests |  |  | 2 |  |  |  |  | — |  |  |  | (2 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (2 | )
Other reclassifications of noncontrolling interests |  |  | (9 | ) |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 12 |  |  |  | 12 |
Share-based compensation |  |  | — |  |  |  |  | — |  |  |  | 2 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2 |
Balance, June 30, 2024 |  |  | 324 |  |  |  |  | 1 |  |  |  | 2,190 |  |  |  | (13 | ) |  |  | (3,619 | ) |  |  | 238 |  |  |  | (1,203 | )
Comprehensive income (loss) |  |  | 13 |  |  |  |  | — |  |  |  | — |  |  |  | 5 |  |  |  | (391 | ) |  |  | 23 |  |  |  | (363 | )
Distributions to noncontrolling interests |  |  | (10 | ) |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (26 | ) |  |  | (26 | )
Purchases of subsidiary shares from noncontrolling interests |  |  | — |  |  |  |  | — |  |  |  | (1 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1 | )
Adjustment to redemption value of redeemable noncontrolling interests |  |  | (1 | ) |  |  |  | — |  |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1 |
Disposition of less-than-wholly owned entity |  |  | (4 | ) |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (4 | ) |  |  | (4 | )
Share-based compensation |  |  | — |  |  |  |  | — |  |  |  | 4 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4 |
Balance, September 30, 2024 |  | $ | 322 |  |  |  | $ | 1 |  |  | $ | 2,194 |  |  | $ | (8 | ) |  | $ | (4,010 | ) |  | $ | 231 |  |  | $ | (1,592 | )
The following schedule presents the reconciliation of the carrying amount of total equity, equity attributable to the Company’s stockholders, and equity attributable to the noncontrolling interests as of September 30, 2023, and during each of the three-month periods following December 31, 2022 (in millions):
|  |  |  |  |  | Community Health Systems, Inc. Stockholders |  |  |  |  |  |  |
|  | Redeemable Noncontrolling Interest |  |  |  | Common Stock |  |  | Additional Paid-In Capital |  |  | Accumulated Other Comprehensive (Loss) Income |  |  | Accumulated Deficit |  |  | Noncontrolling Interest |  |  | Total Stockholders’ Deficit |
Balance, December 31, 2022 |  | $ | 541 |  |  |  | $ | 1 |  |  | $ | 2,084 |  |  | $ | (21 | ) |  | $ | (3,431 | ) |  | $ | 92 |  |  | $ | (1,275 | )
Comprehensive income (loss) |  |  | 21 |  |  |  |  | — |  |  |  | — |  |  |  | 3 |  |  |  | (51 | ) |  |  | 11 |  |  |  | (37 | )
Distributions to noncontrolling interests |  |  | (33 | ) |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (11 | ) |  |  | (11 | )
Purchases of subsidiary shares from noncontrolling interests |  |  | (1 | ) |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Contributions from noncontrolling interests |  |  | 1 |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1 |  |  |  | 1 |
Adjustment to redemption value of redeemable noncontrolling interests |  |  | 32 |  |  |  |  | — |  |  |  | (32 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (32 | )
Cancellation of restricted stock for tax withholdings on vested shares |  |  | — |  |  |  |  | — |  |  |  | (4 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (4 | )
Share-based compensation |  |  | — |  |  |  |  | — |  |  |  | 6 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 6 |
Balance, March 31, 2023 |  |  | 561 |  |  |  |  | 1 |  |  |  | 2,054 |  |  |  | (18 | ) |  |  | (3,482 | ) |  |  | 93 |  |  |  | (1,352 | )
Comprehensive income (loss) |  |  | 28 |  |  |  |  | — |  |  |  | — |  |  |  | (1 | ) |  |  | (38 | ) |  |  | 11 |  |  |  | (28 | )
Distributions to noncontrolling interests |  |  | (21 | ) |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (19 | ) |  |  | (19 | )
Contributions from noncontrolling interests |  |  | — |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1 |  |  |  | 1 |
Purchases of subsidiary shares from noncontrolling interests |  |  | (6 | ) |  |  |  | — |  |  |  | 5 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 5 |
Noncontrolling interest in acquired entity |  |  | 7 |  |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Adjustment to redemption value of redeemable noncontrolling interests |  |  | 14 |  |  |  |  | — |  |  |  | (14 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (14 | )
Share-based compensation |  |  | — |  |  |  |  | — |  |  |  | 4 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4 |
Balance, June 30, 2023 |  |  | 583 |  |  |  |  | 1 |  |  |  | 2,049 |  |  |  | (19 | ) |  |  | (3,520 | ) |  |  | 86 |  |  |  | (1,403 | )
Comprehensive income (loss) |  |  | 12 |  |  |  |  | — |  |  |  | — |  |  |  | (3 | ) |  |  | (91 | ) |  |  | 27 |  |  |  | (67 | )
Distributions to noncontrolling interests |  |  | (8 | ) |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (17 | ) |  |  | (17 | )
Other reclassifications of noncontrolling interests |  |  | (265 | ) |  |  |  | — |  |  |  | 122 |  |  |  | (1 | ) |  |  | — |  |  |  | 145 |  |  |  | 266 |
Adjustment to redemption value of redeemable noncontrolling interests |  |  | 7 |  |  |  |  | — |  |  |  | (7 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (7 | )
Share-based compensation |  |  | — |  |  |  |  | — |  |  |  | 6 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 6 |
Balance, September 30, 2023 |  | $ | 329 |  |  |  | $ | 1 |  |  | $ | 2,170 |  |  | $ | (23 | ) |  | $ | (3,611 | ) |  | $ | 241 |  |  | $ | (1,222 | )
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Net loss attributable to Community Health Systems, Inc. stockholders |  | $ | (391 | ) |  | $ | (91 | ) |  | $ | (446 | ) |  | $ | (180 | )
Transfers to the noncontrolling interests: |  |  |  |  |  |  |  |  |  |  |  |
Net increase in Community Health Systems, Inc. paid-in-capital for purchase of subsidiary partnership interests |  |  | 1 |  |  |  | — |  |  |  | 4 |  |  |  | 5 |
Net transfers to the noncontrolling interests |  |  | 1 |  |  |  | — |  |  |  | 4 |  |  |  | 5 |
Change to Community Health Systems, Inc. stockholders’ deficit from net loss attributable to Community Health Systems, Inc. stockholders and transfers to noncontrolling interests |  | $ | (390 | ) |  | $ | (91 | ) |  | $ | (442 | ) |  | $ | (175 | )

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for equity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration